<DOC>
	<DOCNO>NCT00004662</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety efficacy synthetic dehydroepiandrosterone , GL701 , woman active systemic lupus erythematosus .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Placebo-Controlled Study Dehydroepiandrosterone Women With Active Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . Patients stratify participate institution . Patients randomly assign daily oral dehydroepiandrosterone placebo 52 week . Patients evaluate every 13 week study return follow-up 6 week completion therapy . Concurrent therapy estrogen replacement stable dos prednisone , azathioprine , methotrexate ( folate supplementation ) , hydroxychloroquine , nonsteroidal anti-inflammatory drug allow . Other investigational medication immunosuppressant prohibit .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Systemic lupus erythematosus 1982 American College Rheumatology criterion Diagnosed least 6 month Systemic Lupus Activity Measure score least 7 Points erythrocyte sedimentation rate exclude SLEDAI score great 2 screen qualify visit Prior/Concurrent Therapy No prior participation dehydroepiandrosterone ( DHEA ) study No investigational agent within long 30 day 10 halflives agent Prednisone ( equivalent ) dose 0 10 mg/day Unchanged least 6 week prior entry At least 3 month since immunosuppressant azathioprine methotrexate , include : DHEA Adrenocorticotropin hormone Androgens Cyclophosphamide Cyclosporine Immune globulin At least 6 week since change azathioprine , methotrexate , hydroxychloroquine Patient Characteristics Renal : No requirement hemodialysis Cardiovascular : No serious abnormality electrocardiogram Other : No hypersensitivity DHEA inactive ingredient GL701 formulation , i.e. , cornstarch , lactose , magnesium stearate No history breast cancer reproductive tract malignancy Cervical carcinoma eligible surgically cure , i.e. , evidence disease 5 year No condition would prevent compliance followup , e.g . : Alcoholism Drug addiction Acute withdrawal chemical dependency Psychiatric disease No pregnant nursing woman Negative pregnancy test require fertile woman Reliable contraception require fertile woman No estrogencontaining oral contraceptive study At least 3 week since estrogencontaining oral contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>